Attached files

file filename
EX-99.1 - EX-99.1 - Avalo Therapeutics, Inc.cerc-20160720ex9911b330d.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2016

 

 

Cerecor Inc.

(Exact name of Registrant as Specified in Its Charter) 

 

 

 

 

 

 

 

Delaware

 

001-37590

 

45-0705648

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer Identification No.)

 

 

 

 

 

 

 

400 E. Pratt Street

Suite 606

Baltimore, Maryland

 

21202

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (410) 522-8707

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 7.01.Regulation FD Disclosure.

 

On July 20, 2016, Cerecor Inc. (the “Company”) issued a press release, further described in Item 8.01 below, in connection with its research and development grant award from the National Institute on Alcohol Abuse and Alcoholism (“NIAAA”) at the National Institutes of Health. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01.Other Events.

 

Research and Development Grant from the NIAAA at the National Institutes of Health

 

On July 20, 2016, the Company announced that it has been awarded a research and development grant of $1.0 million from the NIAAA. The grant provides the Company with additional resources to progress the development of CERC-501 for the treatment of alcohol use disorder.

 

Item 9.01.Financial Statements and Exhibits.

 

 

 

 

Exhibit

No.

  

Description

 

 

 

99.1

 

Press Release, dated July 20, 2016, entitled “Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health.”

 

 

 

2


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

Cerecor Inc.

 

 

 

 

 

 

By:

/s/ Mariam Morris

 

 

 

Mariam Morris

 

 

 

Chief Financial Officer

 

Date:   July 20, 2016

3


 

 

EXHIBIT INDEX

 

 

 

 

Exhibit

No.

  

Description

 

 

 

99.1

 

Press Release, dated July 20, 2016, entitled “Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health.”

 

 

 

4